Cargando…

Do the data really support ordering fragile X testing as a first-tier test without clinical features?

PURPOSE: Current guidelines recommend first-tier chromosome microarray analysis (CMA) and fragile X syndrome (FX) testing for males with isolated intellectual disabilities/learning delay (ID/LD) and autism spectrum disorders (ASDs). METHODS: Males in our clinic with ID/LD or ASD (310) were analyzed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weinstein, Veronique, Tanpaiboon, Pranoot, Chapman, Kimberly A, Ah Mew, Nicholas, Hofherr, Sean
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702277/ https://www.ncbi.nlm.nih.gov/pubmed/28541279 http://dx.doi.org/10.1038/gim.2017.64

Ejemplares similares

Role of elosulfase alfa in mucopolysaccharidosis IVA
por: Regier, Debra S, et al.
Publicado: (2016)

The fragile X syndrome–autism comorbidity: what do we really know?
por: Abbeduto, Leonard, et al.
Publicado: (2014)

The second-tier status of fragile X syndrome testing for unexplained intellectual disability/global developmental delay in the era of next-generation sequencing
por: Zhang, Wen, et al.
Publicado: (2022)

Fragile X syndrome: Diagnostic and carrier testing
por: Sherman, Stephanie, et al.
Publicado: (2005)

Molecular Testing for Fragile X: Analysis of 5062 Tests from 1105 Fragile X Families—Performed in 12 Clinical Laboratories in Spain
por: Tejada, María-Isabel, et al.
Publicado: (2014)

Do you really want to test them all at cold?
por: Sanfilippo, S
Publicado: (2003)

Does admission order form design really matter? A reduction in urea blood test ordering
por: Mathura, Pamela, et al.
Publicado: (2021)

The Erythrocyte Fragility Test
por: Alport, A. Cecil
Publicado: (1929)

Disturbance–diversity models: what do they really predict and how are they tested?
por: Svensson, J. Robin, et al.
Publicado: (2012)

Do molecular tests really differentiate malignant IPMNS from benign?
por: Basar, Omer, et al.
Publicado: (2016)

EMQN best practice guidelines for the molecular genetic testing and reporting of fragile X syndrome and other fragile X-associated disorders
por: Biancalana, Valérie, et al.
Publicado: (2015)

Effects of triheptanoin (UX007) in patients with long‐chain fatty acid oxidation disorders: Results from an open‐label, long‐term extension study
por: Vockley, Jerry, et al.
Publicado: (2020)

The Fragility of Individual-Based Explanations of Social Hierarchies: A Test Using Animal Pecking Orders
por: Chase, Ivan D., et al.
Publicado: (2016)

Diagnostic parameters of modified two-tier testing in European patients with early Lyme disease
por: Baarsma, ME, et al.
Publicado: (2020)

Fragile X syndrome and fragile X-associated disorders
por: Rajaratnam, Akash, et al.
Publicado: (2017)

Storage management solutions and performance tests at the INFN Tier-1
por: Bencivenni, M, et al.
Publicado: (2008)

Chromosomal Microarray Analysis as First-Tier Genetic Test for Schizophrenia
por: Chen, Chia-Hsiang, et al.
Publicado: (2021)

Costly coagulation profile tests prior to performing breast biopsies: Do we really need it?
por: Ashkar, Laila K., et al.
Publicado: (2016)

The performance of genome sequencing as a first-tier test for neurodevelopmental disorders
por: van der Sanden, Bart P. G. H., et al.
Publicado: (2022)

A solution to limitations of cognitive testing in children with intellectual disabilities: the case of fragile X syndrome
por: Hessl, David, et al.
Publicado: (2008)

Cascade Testing for Fragile X Syndrome in a Rural Setting in Cameroon (Sub-Saharan Africa)
por: Kengne Kamga, Karen, et al.
Publicado: (2020)

Can We Really Test People for Potential?
por: Rebele, Reb
Publicado: (2019)

Fragile X Syndrome
por: McLennan, Yingratana, et al.
Publicado: (2011)

Targeting fragile X
por: Gantois, Ilse, et al.
Publicado: (2002)

Fragile X Premutation
por: Tassone, Flora, et al.
Publicado: (2014)

Fragile X Syndrome
por: Saldarriaga, Wilmar, et al.
Publicado: (2014)

Do the Lower Body Strength Assessment Tests in the Spanish Navy Really Measure What They Purport to Measure?
por: Vila, Mª Helena, et al.
Publicado: (2022)

A tiered-layered-staged model for informed consent in personal genome testing
por: Bunnik, Eline M, et al.
Publicado: (2013)

Combining newborn metabolic and DNA analysis for second-tier testing of methylmalonic acidemia
por: Peng, Gang, et al.
Publicado: (2018)

Aerogels are not regulated as nanomaterials, but can be assessed by tiered testing and grouping strategies for nanomaterials
por: Keller, Johannes G., et al.
Publicado: (2021)

Genomic Sequencing as a First-Tier Screening Test and Outcomes of Newborn Screening
por: Chen, Ting, et al.
Publicado: (2023)

Do We Really Understand Spine Treatments and Science Around the World?
por: Wiechert, Karsten, et al.
Publicado: (2017)

Are We Ready for Fragile X Newborn Screening Testing?—Lessons Learnt from a Feasibility Study
por: Wotton, Tiffany, et al.
Publicado: (2018)

Preoperative Cardiac Stress Tests Ordered in the Preoperative Evaluation Clinic: A Retrospective Review of Ordering Patterns
por: Weinstein, Adam S., et al.
Publicado: (2019)

How Do They Really Arise?
Publicado: (1921)

Do we really listen?
por: Vázquez, P. García, et al.
Publicado: (2021)

Do the Fittest Really Survive?
por: Towner, Ausburn
Publicado: (1879)

Grazyna Jasienska, The Fragile Wisdom
por: Weinstein, Maxine
Publicado: (2013)

APP Causes Hyperexcitability in Fragile X Mice
por: Westmark, Cara J., et al.
Publicado: (2016)

Mouse models of the fragile X premutation and fragile X-associated tremor/ataxia syndrome
por: Berman, Robert F, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7sbrgm7d1l7cf8pc6hrlu11s6g